Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

泰 達

泰 達 天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
（Stock Code：8189）

Clarification Announcement
Grant of Award Shares under the Share Award Scheme

Reference is made to the announcement made by the Company dated 21 October 2026 in relation to the grant of award shares (the "**Announcement**"). Unless otherwise defined, terms capitalised in this announcement shall have the same meanings as in the Announcement.

The Company would like to clarify and supplement that the grant of the Award Shares of 4,000,000 to the Grantee would result in the Shares issued and to be issued in respect of all awards granted to the Grantee (excluding any awards lapsed in accordance with the terms of the applicable scheme) in the 12-month period up to and including the Grant Date representing in aggregate approximately 0.278% of the total number of issued H Shares and approximately 0.187% of the total number of issued Shares (excluding treasury Shares) as at the Grant Date.

Given that the Grantee is an employee of the Group, being a shareholder and a director of a subsidiary of the Company, the grant of the Award Shares would not result in the total number of Shares issued and to be issued in respect of all the awards granted to the Grantee and, if any, the share options and other share awards granted under any other share scheme(s) to the Grantee (excluding any awards and any share options and other share awards lapsed in accordance with the terms of the applicable schemes) in the 12-month period up to and including the Grant Date exceeding 1% of (i) the total number of issued H Shares and (ii) the total number of issued Shares

(excluding treasury Shares) as at the Grant Date. As such, the grant of the Award Shares to the Grantee would not be subject to approval by the Shareholders pursuant to Rule 23.04(4) of the GEM Listing Rules.

Except as disclosed above, all the other information contained in the Announcement remains unchanged. This clarification announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
26 October 2026

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li and Mr. YangZeng; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing, Mr. Wang Lei and Mr. Xia Alan Zhe; the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the Stock Exchange's website at http://www.hkexnews.hk on the "Latest Listed Company Information" page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com .